ID   Ma-Mel-38
AC   CVCL_A174
SY   MaMel38
DR   cancercelllines; CVCL_A174
DR   Cosmic; 1467754
DR   Cosmic; 1846619
DR   Cosmic; 2163854
DR   Cosmic; 2686403
DR   ESTDAB; ESTDAB-171
DR   GEO; GSM437005
DR   IGRhCellID; MaMel38
DR   Progenetix; CVCL_A174
DR   Wikidata; Q54903792
RX   PubMed=17311103;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Ala60fs (c.181_202delinsAC) (p.Gly75fs, c.224_45delinsACG); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ESTDAB=ESTDAB-171
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 8,10
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 10
ST   FGA: 25
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 24
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//